



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/889,904	09/10/2001	Dennis Murphy	P50869	3015

7590

08/27/2002

Glaxosmithkline
Corporate Intellectual Property UW2220
PO Box 1539
King of Prussia, PA 19406-0939

EXAMINER

DELACROIX MUIRHEI, CYBILLE

ART UNIT

PAPER NUMBER

1614

DATE MAILED: 08/27/2002

9

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE
Pat nt and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/889,904		MURPHY et al.	

EXAMINER	
ART UNIT	PAPER NUMBER
1614	

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

The reply filed on June 4, 2002 is not fully responsive to the prior Office action because of the following omission(s) or matter(s): Applicant's reply does not clearly address the office action mailed Dec. 20, 2001. Specifically, Applicant has not presented arguments pointing out the distinctions believed to render the newly added claims patentable over the applied prior art. Applicant has failed to point out the patentable novelty believed to be embodied by the claims nor has Applicant shown how the amendments avoid the prior art of record. The reply must present arguments pointing out the specific distinctions believed to render the claims, including any newly presented claims, patentable over any applied references. Additionally, in amending in response to a rejection of claims in an application, the applicant must clearly point out the patentable novelty which he or she thinks the claims present in view of the state of the art disclosed by the references cited. The applicant or patent owner must also show how the amendments avoid such references. Please see 37 CFR 1.111(b) and (c). Since the above-mentioned reply appears to be *bona fide*, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cybille Delacroix-Muirheid whose telephone number is (703) 306-3227. The examiner can normally be reached on Tue-Fri from 8:30 to 6:00. The examiner can also be reached on alternate Mondays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel, can be reached on (703) 308-4725. The fax phone number for this Group is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the

Group receptionist whose telephone number is (703) 308-1235.

CDM



Aug. 26, 2002



Cybille Delacroix-Muirheid
Patent Examiner Group 1600